{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:03:35Z","timestamp":1789689815419,"version":"4.0.1"},"publisher-location":"Cham","reference-count":26,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030783105","type":"print"},{"value":"9783030783112","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-78311-2_10","type":"book-chapter","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T13:55:25Z","timestamp":1633874125000},"page":"167-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systemic Mastocytosis: Advances in Diagnosis and Current Management"],"prefix":"10.1007","author":[{"given":"Sheeja T.","family":"Pullarkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,10]]},"reference":[{"key":"10_CR1","unstructured":"Swerdlow SH et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edn. International Agency for Research on Cancer, Lyon, France"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK et al (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92:10560","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","volume":"101","author":"C Ustun","year":"2016","unstructured":"Ustun C, Arock M, Kluin-Nelemans HC et al (2016) Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica 101(10):1133\u20131143","journal-title":"Haematologica"},{"key":"10_CR4","doi-asserted-by":"crossref","unstructured":"Schaab J, Schnittger S. Sotlar K et al (2013) Comprehensive mutational profiling in advanced systemic Mastocytosis. Blood 12(14):460\u2013466","DOI":"10.1182\/blood-2013-04-496448"},{"issue":"1","key":"10_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Schnittger S et al (2016) Additional mutations in SRSF2, ASXL1 and or RUNX1identify a high risk group of patients with KIT D816V(+) advances systemic mastocytosis. Leukemia 30(1):136\u2013143","journal-title":"Leukemia"},{"key":"10_CR6","doi-asserted-by":"crossref","unstructured":"Jawhar m, Schwaab J, Schnittger S et al (2015) Molecular profiling of myeloid progenitor cells in multimutated advanced systemic mastocytosis identifies KITD8116V as a distinct and late event Leukmaia 29(5):1115\u20131122","DOI":"10.1038\/leu.2015.4"},{"issue":"5","key":"10_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3324\/haematol.2013.095133","volume":"99","author":"K Hanssens","year":"2014","unstructured":"Hanssens K, Brenet F, Agopian J et al (2014) SRSF2-p95 hotspot mutation is hifhly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica 99(5):830\u2013835","journal-title":"Haematologica"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","volume":"100","author":"AS Yavuz","year":"2002","unstructured":"Yavuz AS, Lipsky PE, Yavuz S et al (2002) Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 100:661","journal-title":"Blood"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ebiom.2019.03.089","volume":"43","author":"J Grootens","year":"2019","unstructured":"Grootens J, Ungerstedt JS, Ekoff M et al (2019) Single cell analysis reveals the KIT D816V mutation in hematopoietic stem and progenitor cells in systemic mastocytosis. EBioMedicine 43:150\u2013158","journal-title":"EBioMedicine"},{"issue":"5","key":"10_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/gcc.22526","volume":"57","author":"N Naumann","year":"2018","unstructured":"Naumann N, Jawhar M, Schwaab J (2018) Incidence and prognostic impact of cytogenetic aberrations in patients with systemic Mastocytosis. Genes Chromosomes Cancer 57(5):252\u2013259","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.leukres.2006.03.006","volume":"31","author":"V Pullarkat","year":"2007","unstructured":"Pullarkat V, Bedell V, Kim Y et al (2007) Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 31(2):261\u2013265","journal-title":"Leuk Res"},{"key":"10_CR12","doi-asserted-by":"crossref","unstructured":"Pullarkat VA, Bueso-Ramos C, Lai R et al (2003) Systemic mastocytosis associated with clonal hematological non mast cell lineage disease: analysis of clinicopathologic features and activating c-kit mtations. Am J Hematol 73(1):12\u201317","DOI":"10.1002\/ajh.10322"},{"key":"10_CR13","doi-asserted-by":"crossref","unstructured":"Morgado JM, Perbellini O, Johnson RC et al (2013) CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology 63:780\u2013787","DOI":"10.1111\/his.12221"},{"key":"10_CR14","doi-asserted-by":"crossref","unstructured":"Sotlar K, Cerny-Reiterer S, Petat-Dutter K et al (2011) Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 24:585\u2013595","DOI":"10.1038\/modpathol.2010.224"},{"issue":"16","key":"10_CR15","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2019000932","volume":"35","author":"A Reiter","year":"2020","unstructured":"Reiter A, George TI, Gotlib J (2020) New developments in diagnosis, prognostication and treatment of advanced systemic mastocytosis. Blood 35(16):1365\u20131376","journal-title":"Blood"},{"issue":"12","key":"10_CR16","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.leukres.2007.04.008","volume":"31","author":"Y Kim","year":"2007","unstructured":"Kim Y, Weiss LM, Chen YY, Pullarkat V (2007) Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma. Leuk Res 31(12):1749\u20131754","journal-title":"Leuk Res"},{"issue":"4","key":"10_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1309\/AJCP1Q0YSXEAHNKK","volume":"140","author":"RC Johnson","year":"2013","unstructured":"Johnson RC, Savage NM, Chiang T et al (2013) Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol 140(4):525\u2013535","journal-title":"Am J Clin Pathol"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","volume":"94","author":"A Pardanani","year":"2019","unstructured":"Pardanani A (2019) Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol 94:363\u2013377","journal-title":"Am J Hematol"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","volume":"121","author":"A Pardanani","year":"2013","unstructured":"Pardanani A (2013) How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 121:3085\u20133094","journal-title":"Blood"},{"key":"10_CR20","doi-asserted-by":"crossref","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI et al (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374:2530\u20132541","DOI":"10.1056\/NEJMoa1513098"},{"key":"10_CR21","doi-asserted-by":"crossref","unstructured":"Radia D, Deininger M, Gotlib J et al (2019) Avapritinib, a potent and selective inhibitor of KIT D816V induces complete and durable responses in patients with advanced systemic mastocytosis European Hematology Association Congress. Amsterdam, The Netherlands","DOI":"10.1097\/01.HS9.0000561600.89121.38"},{"key":"10_CR22","doi-asserted-by":"crossref","unstructured":"Gotlib J, Pardanani A, Akin C et al (2013) International working group-myeloproliferative neoplasms research and treatment (IWG-MRT) & European competence network on mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 121","DOI":"10.1182\/blood-2012-09-458521"},{"key":"10_CR23","doi-asserted-by":"crossref","unstructured":"Kluin \u2013Nelemans C, Oldhoff JM, Van Doormaal JJ (2003) Cladaribine therapy for systemic mastocytosis. Blood 102: 4270\u20134276","DOI":"10.1182\/blood-2003-05-1699"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","volume":"119","author":"P Casassus","year":"2002","unstructured":"Casassus P, Caillat-Vigneron N, Martin A et al (2002) Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 119:1090\u20131097","journal-title":"Br J Haematol"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","volume":"32","author":"C Ustin","year":"2014","unstructured":"Ustin C, Reiter A, Scott BL (2014) Hematopoietic stem cell transplantation for advanced systemic mastocytosis. J Clin Oncol 32:3264\u20133274","journal-title":"J Clin Oncol"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","volume":"22","author":"C Ustun","year":"2016","unstructured":"Ustun C, Gotlib J, Popat U et al (2016) Consensus opinion on allogeneic hematopoietuc cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant 22:1348\u20131356","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cancer Treatment and Research","Biology and Treatment of Leukemia and Bone Marrow Neoplasms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-78311-2_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T19:26:42Z","timestamp":1699644402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-78311-2_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030783105","9783030783112"],"references-count":26,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-78311-2_10","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"10 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}